<SEC-DOCUMENT>0000719135-18-000035.txt : 20180516
<SEC-HEADER>0000719135-18-000035.hdr.sgml : 20180516
<ACCEPTANCE-DATETIME>20180516113746
ACCESSION NUMBER:		0000719135-18-000035
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180516
DATE AS OF CHANGE:		20180516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOVIE MEDICAL Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224677
		FILM NUMBER:		18839275

	BUSINESS ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577
		BUSINESS PHONE:		800-537-2790

	MAIL ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>bvx_20180516xs-3amend1.htm
<DESCRIPTION>BVX_S-3/A_2018.05.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9E96D479C739569F9EB7EF309F8F820F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRE-EFFECTIVE AMENDMENT NUMBER 1 TO</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM S-3</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">REGISTRATION STATEMENT</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Under</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">THE SECURITIES ACT OF 1933</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BOVIE MEDICAL CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:30%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">11-2644611</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">5115 Ulmerton Road</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Clearwater, FL 33760 </font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(727) 384-2323 </font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Charles D. Goodwin, II</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Chief Executive Officer</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">5115 Ulmerton Road</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Clearwater, Florida 33760</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(727) 384-2323</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">Copy to:</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adam P. Silvers, Esq.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Michael S. Williams, Esq.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Ruskin Moscou Faltischek, P.C.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1425 RXR Plaza</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">East Tower, 15</font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">th</sup></font><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#32;Floor</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Uniondale, New York 11556-1425</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(516) 663-6519</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">______________________________</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Approximate date of commencement of proposed sale to the public:</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">From time to time after the effective date of this registration statement.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:8pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: </font><font style="font-family:Wingdings;font-size:9.5pt;font-weight:bold;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:8pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or intent reinvestments plans, check the following box: </font><font style="font-family:Wingdings;font-size:9.5pt;">&#253;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:8pt;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="font-family:Wingdings;font-size:9.5pt;font-weight:bold;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:8pt;">If this Form is a post effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. </font><font style="font-family:Wingdings;font-size:9.5pt;font-weight:bold;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:8pt;">If this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. </font><font style="font-family:Wingdings;font-size:9.5pt;font-weight:bold;">o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:8pt;">If this form is a post-effective amendment to a registration statement filed pursuant General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. </font><font style="font-family:Wingdings;font-size:9.5pt;font-weight:bold;">o</font></div><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non accelerated filer, or a smaller reporting company.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:22%;"></td><td style="width:3%;"></td><td style="width:49%;"></td><td style="width:23%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;font-weight:bold;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;font-weight:bold;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;font-weight:bold;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">o</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">o</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752522</font></div></div><hr style="page-break-after:always"><div><a name="s69C96D58A335549EB9AA3DF95D0D7FE5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:36%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:16%;"></td><td style="width:16%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CALCULATION OF REGISTRATION FEE</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title of Each Class of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities to be Registered</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount to be Registered</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1)(2)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Proposed Maximum </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Offering Price Per Security (3)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Proposed Maximum Aggregate Offering Price (4)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Registration Fee (4)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Stock, par value $.001 per share</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)(2)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred Stock, par value $.001 per share</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)(2)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt Securities</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)(2)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)(2)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Units (5)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)(2)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)(2)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$25,000,000</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$3,112.50</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are being registered hereunder such indeterminate number of shares of common stock, such indeterminate number of shares of preferred stock, such indeterminate principal amount of debt securities, such indeterminate number of warrants to purchase common stock and/or preferred stock and such indeterminate number of units as may be sold by the Registrant from time to time, which together shall have an aggregate initial offering price not to exceed $25,000,000. If any debt securities are issued at an original issue discount, then the offering price of such debt securities shall be in such greater principal amount at maturity as shall result in an aggregate offering price not to exceed $25,000,000, less the aggregate dollar amount of all securities previously issued hereunder. Any securities registered hereunder may be sold separately or as units with the other securities registered hereunder. The proposed maximum offering price per unit will be determined, from time to time, by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder. The securities registered hereunder also include such indeterminate number of shares of common stock and amount of debt securities as may be issued upon conversion of or exchange for common stock, preferred stock or debt securities that provide for conversion or exchange, upon exercise of warrants or pursuant to the anti-dilution provisions of any of such securities. In addition, this registration statement also relates to an indeterminate number of shares of common stock that may be issued upon stock splits, stock dividends or similar transactions in accordance with Rule 416 under the Securities Act of 1933.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the restrictions of Section 713 of the NYSE MKT Company Guide, the Registrant may sell no more than 20% of its shares in a primary offering, in any given year if such shares are sold below the greater of book value or market value.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The proposed maximum offering price per class of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder. The principal amount of any debt securities issued with original issue discount will be greater at maturity. If any debt securities are issued with original issue discount, then the offering price of such debt securities shall be in such greater principal amount as shall result in an aggregate initial offering price not to exceed $25,000,000, less the aggregate dollar amount of all securities previously issued hereunder.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) of the Securities Act of 1933.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consisting of some or all of the securities listed above, in any combination, including common stock, preferred stock, debt securities and warrants.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752522</font></div></div><hr style="page-break-after:always"><div><a name="sB3CD103C685A5170BFF892424B9EB518"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Explanatory Note</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Pre-Effective Amendment Number 1 to the Registration Statement on Form S-3 is being filed solely to include our Quarterly Report on Form 10-Q for the period ended March 31,2018, filed with the SEC on May 15, 2018 under the section, Incorporation of Certain Information by Reference.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752522</font></div></div><hr style="page-break-after:always"><div><a name="sDC713DC772A15515843D5CE904BC9632"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ff0000;">THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THESE SECURITIES WILL NOT BE SOLD UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES, AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBJECT TO COMPLETION, DATED </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">May&#160;16, 2018</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="a2017bvxlogoa03.jpg" alt="a2017bvxlogoa03.jpg" style="height:84px;width:285px;"></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROSPECTUS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BOVIE MEDICAL CORPORATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">$</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">25,000,000</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Debt Securities</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Units</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may offer and sell from time to time in one or more offerings up to $25,000,000 in the aggregate of: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shares of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shares of our preferred stock, in one or more series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our debt securities, in one or more series, which may be either senior or subordinated debt securities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warrants to purchase shares of our common stock or preferred stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">units consisting of shares of common stock, debt securities and/or warrants to purchase shares of common stock and/or debt securities in any combination; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any combination of the foregoing.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each time we offer securities, we will provide the specific terms of the securities offered in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The securities offered by this prospectus may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers. We will set forth the names of any underwriters or agents and any applicable fees, commissions, discounts and over-allotments in an accompanying prospectus supplement. For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution&#8221; in this prospectus and in the applicable prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is listed on the NYSE MKT under the symbol &#8220;BVX.&#8221; The last reported sale price of our common stock on April 30, 2018 was $3.49 per share. As of April 30, 2018, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $87,621,706. For purposes of this disclosure, shares of common stock held by persons who are known by us to beneficially own more than 5% of the outstanding shares of common stock and shares held by officers and directors of the Registrant have been excluded in that such persons may be deemed to be affiliates. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on, and includes, the date of this prospectus.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE HEADING &#8220;RISK FACTORS&#8221; ON PAGE 9 OF THIS PROSPECTUS AS WELL AS THOSE CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE DATE OF THIS PROSPECTUS IS </font><font style="font-family:inherit;font-size:10pt;">MAY&#160;16, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s6024562F71CA55909B9C5E39D750C120"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:88%;"></td><td style="width:12%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TABLE OF CONTENTS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s1E208836E6A852A0B18FE6021D8395E9"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">ABOUT THIS PROSPECTUS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s1E208836E6A852A0B18FE6021D8395E9">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sD90CC544A36C598295984EE5E6B34859"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">SUMMARY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sD90CC544A36C598295984EE5E6B34859">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s4213BD56E3A850889114A8BD87E540DB"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s4213BD56E3A850889114A8BD87E540DB">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s0818874BEA025D88BB27AB10CC939E8F"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s0818874BEA025D88BB27AB10CC939E8F">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sE845B2C7F1F65375A8925C86544F0F2B"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">USE OF PROCEEDS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sE845B2C7F1F65375A8925C86544F0F2B">10</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sCDA4A8FD1B2053B1BAEF63BB28C863E0"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">DESCRIPTION OF CAPITAL STOCK</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sCDA4A8FD1B2053B1BAEF63BB28C863E0">10</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sB916402F71B451E383A880E106E0EC1B"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">DESCRIPTION OF DEBT SECURITIES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sB916402F71B451E383A880E106E0EC1B">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s94E320F608EE536B97726E71975385B5"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">DESCRIPTION OF WARRANTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s94E320F608EE536B97726E71975385B5">18</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sE0BCA20F6B205AB389ABAA94FBD8F0A1"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">DESCRIPTION OF UNITS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sE0BCA20F6B205AB389ABAA94FBD8F0A1">19</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s9FFF09CBC8935303B7406969B2798F1E"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">PLAN OF DISTRIBUTION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s9FFF09CBC8935303B7406969B2798F1E">19</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s53B51017ABD25A88B669B0A71071C352"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">LEGAL MATTERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s53B51017ABD25A88B669B0A71071C352">21</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sFF2AD47012B95FF595A8D49701155F54"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">EXPERTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#sFF2AD47012B95FF595A8D49701155F54">21</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s8C428EEFB3335E6194C53C5C32DC1725"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s8C428EEFB3335E6194C53C5C32DC1725">21</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s0C1B50EB84885319BA79DE2D481082AA"><font style="font-family:inherit;font-size:11pt;text-decoration:none;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;text-decoration:none;" href="#s0C1B50EB84885319BA79DE2D481082AA">21</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should read this prospectus, including all documents incorporated herein by reference, together with additional information described under &#8220;Where You Can Find More Information.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You may obtain the information incorporated by reference without charge by following the instructions under &#8220;Where You Can Find More Information.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752522</font></div></div><hr style="page-break-after:always"><div><a name="s1E208836E6A852A0B18FE6021D8395E9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, in one or more offerings, up to a total dollar amount of $25,000,000. However, in no event will we sell more than one-third (1/3) of our &#8220;public float&#8221; (the market value of our common stock held by non-affiliates) in any twelve (12) month period. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the specific terms of the offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. Each such prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) may also add, update or change information contained in this prospectus or in documents incorporated by reference into this prospectus. We urge you to carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the headings &#8220;Where You Can Find Additional Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; before buying any of the securities being offered. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THIS PROSPECTUS MAY NOT BE USED TO OFFER OR SELL SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should rely only on the information contained or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus. We have not authorized anyone to provide you with different information in addition to or different from that contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find Additional Information.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="sD90CC544A36C598295984EE5E6B34859"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summary highlights selected information from this prospectus or incorporated by reference in this prospectus. This summary does not contain all the information you should consider before investing in our securities. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities referred to under the heading &#8220;Risk Factors&#8221; in this prospectus and contained in the applicable prospectus supplement and any related free writing prospectus, and in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Company</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bovie Medical Corporation (&#8220;Company&#8221;, &#8220;Bovie Medical&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, or &#8220;our&#8221;) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at&#160;5115 Ulmerton Road, Clearwater, FL 33760.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are an energy-based medical device company specializing in developing, manufacturing and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor&#8217;s offices, surgery centers and hospitals worldwide. Our medical devices are marketed through Bovie&#8217;s own well-respected brands (Bovie</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, IDS&#8482; and DERM</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">) and on a private label basis to distributors throughout the world. The Company also leverages its expertise in the design, development and manufacturing of electrosurgical equipment by producing equipment for large, well-known medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for our energy based designs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also the developer of J-Plasma; a patented helium-based plasma surgical product which we believe has the potential to be a transformational product for surgeons.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective is to achieve profitable, sustainable growth by increasing our market share in the advanced energy category, including the commercialization of products that have the potential to be transformational with respect to the results they produce for surgeons and patients. In order to achieve this objective, we plan to leverage our long history in the industry, along with the reputation for quality and reliability that the Bovie brand enjoys within the medical community. At the same time, we will expand our product offerings beyond radio frequency devices, move forward with research and developments projects aimed at creating value within our existing product portfolio, build our pipeline of new complementary products, and utilize multiple channels to bring new and existing products to market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are working to build our position in advanced electrosurgical generators and disposables, which can be used in diversified niche markets with minimally invasive surgical instruments, while furthering our status as a pioneer in plasma technology and its various medical applications.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Subsidiaries</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aaron Medical Industries, Inc. is a wholly-owned Florida corporation based in Clearwater, Florida. It is principally engaged in the business of marketing our medical products through distributors worldwide under the Bovie name.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bovie Bulgaria, EOOD is a wholly-owned limited liability company incorporated under Bulgarian law, located in Sofia, Bulgaria. It is engaged in the business of engineering and manufacturing our electrosurgical and OEM generators and accessories.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Industry</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Healthcare reform has caused consolidation among providers, with hospitals merging, physician practices joining hospitals and institutions combining to form Accountable Care Organizations, to manage patients on an interdisciplinary basis. Although the medical device industry can be challenging and very competitive, we believe it will continue to have a positive, long-term growth trajectory with the number of surgical procedures performed increasing annually as a result of the aging &#8220;baby boomer&#8221; population and other healthcare trends. Additionally, we also anticipate a continued increase in minimally invasive surgical procedures due to ongoing advancements in technology coupled with continued overall pressure to reduce healthcare costs via a reduction in patient trauma and recovery time. Markets will also continue to provide growth opportunities for the medical device industry.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that Bovie Medical has sustainable, competitive advantages in the medical device market for several reasons. We have a long history in electrosurgery. Our inspiration dates back to the first use of an electrosurgical generator in an operating room in the U.S. in 1926 where Dr. William T.&#160;Bovie was present. Thus, the Bovie name is recognized by surgeons the world over for having pioneered the electrosurgery field and is recognized for its outstanding product quality supported by strong engineering and research and development capabilities. This history equates to very strong recognition of the Bovie brand. We believe that our equipment and devices have and will continue to provide better experiences for patients at a lower cost to the healthcare system.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on our intellectual property that we have developed or acquired over the years including patents, trade secrets, technical innovations and various licensing agreements to provide our future growth and build our competitive position. We have been issued&#160;41&#160;patents in the United States and&#160;23&#160;foreign patents. We have&#160;12&#160;pending patent applications in the United States and&#160;9&#160;pending foreign applications. Our intellectual property portfolio for the technology and products related to Advanced Energy products is included in these totals and continues to grow. Specific to Advanced Energy products, we have been issued&#160;21&#160;U.S. and&#160;6&#160;foreign patents and we have&#160;12&#160;U.S. and&#160;9&#160;foreign applications pending. As we continue to expand our intellectual property portfolio we believe it is critical for us to continue to invest in filing patent applications to protect our technology, inventions and improvements. However, we can give no assurance that competitors will not infringe on our patent rights or otherwise create similar or non-infringing competing products that are technically patentable in their own right.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing and Suppliers</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are committed to producing the most technically advanced and highest quality products of their kind available on the market. We manufacture the majority of our products on our premises in Clearwater, Florida and at our facility located in Sofia, Bulgaria, which are certified under the ISO international quality standards and are subject to continuing regulation and routine inspections by the FDA to ensure compliance with regulations relating to our quality system, medical device complaint reporting and adherence to FDA restrictions on promotion and advertising. In addition, we are subject to regulations under the Occupational Safety and Health Act, the Environmental Protection Act and other federal, state and local regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2015, we acquired all of the outstanding shares of Bovie Bulgaria, EOOD. Bovie Bulgaria operates an&#160;18,745&#160;square foot ISO13485 certified and FDA registered manufacturing facility located in the capital city of Sofia, which houses manufacturing, development and assembly operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have collaborative arrangements with three foreign suppliers under which we request the development of certain items and components, which we purchase pursuant to purchase orders. Our purchase order commitments are never more than one year in duration and are supported by our sales forecasts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Three Business Segments</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our business through three reportable operating segments: Core, OEM, and Advanced Energy.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended&#160;December&#160;31, 2017, our Core segment contributed&#160;73.7%&#160;of our consolidated total revenue, our OEM segment contributed&#160;6.7%&#160;of our consolidated total revenue and our Advanced Energy segment contributed&#160;19.6%&#160;of our consolidated total revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Core Segment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Core segment manufactures and markets various medical products, both under private label and the Bovie brands (Bovie, IDS and DERM), to distributors worldwide, which distribute to more than 6,000 hospitals and to doctors and other healthcare facilities. New distributors are contacted through responses to our advertising in international and domestic medical journals and our presence at domestic and international trade shows.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Customers</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We sell our Core products through major distributors which include Cardinal Health, Independent Medical Co-Op Inc. (IMCO), McKesson Medical Surgical, Inc., National Distribution and Contracting Inc. (NDC), Henry Schein, Medline, and Owens &amp; Minor and have manufacturing agreements for private label of certain products with these and others.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Products</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Core products consist of electrosurgery generators and accessories, battery-operated cauteries, lighting, nerve locators, eye-bubbles, penlights, and a variety of other products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Electrosurgery Products</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Electrosurgery is our largest product line and includes desiccators, generators, electrodes, electrosurgical pencils and various ancillary disposable products. These electrosurgical products are used during surgical procedures in gynecology, urology, plastic surgery, dermatology and other surgical markets, including veterinary, for the cutting and coagulation of tissue. It is estimated that electrosurgery is used in 80% of all surgical procedures. Our electrosurgery products fall under two categories, monopolar and bipolar. Monopolar products require the use of a grounding pad attached to the patient for the return of the electrical current, while bipolar products consist of two electrodes; one for the inbound current and one for the return current and therefore do not require the use of a grounding pad.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">DERM 101 and DERM 102</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These effective and economical 10 watt high frequency desiccators provide a low wattage platform for minor in-office skin procedures. We designed these products specifically for family practice physicians, pediatricians and other general practitioners, enabling them to perform simple skin procedures in their offices instead of referring the patient to a specialist saving the patient time and providing additional revenue generating procedures for the physician.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">DERM A942</font><font style="font-family:inherit;font-size:10pt;">&#8482;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Bantam|Pro A952</font><font style="font-family:inherit;font-size:10pt;">&#8482;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;and Specialist|Pro A1250S</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bovie&#8217;s line of electrosurgical generators has been recently updated with added features and to provide a more modern look for today&#8217;s physician office.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The new Bovie DERM A942 is a low powered 40-watt high frequency desiccator designed primarily for dermatology. These units are used mainly for removing skin lesions and growths as well as for coagulation in office-based procedures.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Bovie Bantam|Pro A952 is a 50-watt high frequency desiccator with the added feature of a cut capacity for outpatient surgical procedures. In effect, the Bovie Bantam|Pro is two independent surgical devices in one small package. The Bantam|Pro replaces the Aaron A950 but with the added feature of Bovie NEM (neutral electrode monitoring), a safety feature that reduces the potential for alternate site burns. This unit is designed mainly for use in doctors&#8217; offices and is used in a broad range of specialties including dermatology, gynecology, family practice, urology, plastic surgery and ophthalmology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Bovie Specialist|Pro A1250S is a 120-watt multipurpose electrosurgery generator. The unit features monopolar and bipolar functions with pad sensing and is designed to operate like the larger operating room generator in a reduced size. This product is considered to be ideally suited for office-based procedures in the specialties of gynecology, plastic surgery and urology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bovie Surgi-Center|Pro A2350 - IDS210 and Bovie OR|Pro A3350 - IDS310</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To address market demand for more powerful electrosurgical generators, Bovie developed 200, 300 and 400-watt multipurpose digital electrosurgery generators designed for the surgi-center market and the hospital outpatient and inpatient markets. This equipment includes digital hardware that enables very high parallel data processing throughout the operation or procedure. All data is sampled and processed digitally. For the first time in electrosurgery, generators are able to measure tissue impedance in real time (5,000 times a second) thanks to the utilization of digital technology. The design of these units is based on a digital feedback system. By using dedicated digital hardware in place of a general purpose controller for processing data, our equipment enables the power to be adjusted as the impedance varies, to deliver a consistent clinical effect.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bovie Surgi-Center|Pro A2350 and IDS210 are 200-watt generators that have the capability to be used in the majority of procedures performed today in surgi-center or outpatient settings. Although 200 watts is adequate to do most procedures in the operating room, 300 watts is considered the standard and believed to be what most hospitals and surgi-centers will require. To meet this requirement, we developed the Bovie OR|Pro A3350 - IDS 310. The Bovie OR|Pro and IDS 310 incorporate the best features of the IDS 300 and upgrade its capabilities by providing additional bipolar options, including the 225-watt Bovie bipolar and an auto bipolar feature. The 300 watt units also offer the capability to utilize two pencils with simultaneous activation in fulguration mode. In addition, these newer models meet new standards required to sell these products in many of the global markets. The Bovie IDS 400 is a 400-watt generator designed primarily for sale in markets outside of the United States. These units feature both monopolar and bipolar functions, have pad and tissue sensing and include nine blended cutting setting.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Electrosurgical Disposables</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Resistick</font><font style="font-family:inherit;font-size:10pt;">&#8482;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">II</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Resistick II is a trademarked and proprietary coating that is applied to stainless steel that resist eschar (scab or scar tissue caused by burning) during surgery. We have experienced strong demand for this product since its introduction in 2011 and it represents our continued expansion of the Bovie line of electrosurgical disposables.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disposable Laparoscopic Electrodes</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have introduced a line of disposable laparoscopic electrodes in Resistick coated and stainless steel for use by physicians from a broad group of specialties including gynecology, general surgery and urology. These electrodes are offered in J-hook, L-hook, needle, ball and spatula design and have an adapter included which makes these laparoscopic electrodes usable with a 3/32&#8220; or 4mm plug.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cauteries</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Battery Operated Cauteries</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Battery operated cauteries were originally designed for precise hemostasis (to stop bleeding) in ophthalmology. The current use of cauteries has been substantially expanded to include a broad range of applications. Battery operated cauteries are primarily sterile one-time use products. We have continued to improve our offering and in 2016, had a patent issued covering our snap design cautery. It features a switch mechanism that dramatically reduces the potential for accidental activation. We manufacture one of the broadest lines of cauteries in the world, including but not limited to, a line of replaceable battery and replaceable tip cauteries, which are popular in veterinary and overseas markets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Products</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Battery Operated Medical Lights</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manufacture and market a variety of specialty lighting instruments for use in ophthalmology as well as distribute specialty lighting instruments for general surgery, hip replacement surgery and for the placement of endotracheal tubes in emergency and surgical procedures. We also manufacture and market physicians&#8217; office use penlights.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nerve Locator Stimulator</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manufacture a nerve locator stimulator primarily used for identifying motor nerves in hand and facial reconstructive surgery. This instrument is a sterile, self-contained, battery-operated unit, for one time use.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Competition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We compete with numerous manufacturers and distributors of medical supplies and devices, many of which are large and well-established. With the exception of endoscopic instrumentation, which are sold directly or through distribution partners to the end-user under our own brand, many of our products are private labeled. The majority of the products in our core business are sold through distributors under the Bovie label. The balance is private labeled for major distributors who sell it under their own name. By having private labeled and branded distribution, we are able&#160;to increase our position in the marketplace and compete with much larger organizations. While our private label customers distribute products through their internal sales force, the majority of our products are sold through distributors which increase our sales potential and help level the playing field relative to our large competitors that sell direct. Domestically, we continue to believe that we have a substantial market share in the field of electrosurgical generator manufacturing through our Bovie branded and OEM units.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our main competitors in electrosurgical and accessory markets are Valleylab (a division of Medtronic), Conmed and Erbe Electromedizine. In the&#160;battery-operated&#160;cautery market, our main competitor is Beaver Visitec and in the endoscopic instrumentation market, it is Ethicon (a division of Johnson and Johnson) and Covidien Surgical Solutions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OEM Segment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leverages its expertise in the design, development and manufacturing of electrosurgical equipment by producing equipment for large, well-known medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for our energy based designs. These OEM and private label arrangements and our use of the Bovie brands enable us to gain greater market share for the distribution of our products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Advanced Energy Segment</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Advanced Energy Segment consists primarily of J-Plasma (rebranded as Renuvion</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Cosmetic Technology for the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma/Renuvion system utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision, and minimal invasiveness. The new J-Plasma/Renuvion handpieces with Cool-Coag&#8482; technology deliver the precision of helium plasma energy, the power of traditional monopolar coagulation and the efficiency of plasma beam coagulation - enabling thin-layer ablation and dissection and fast coagulation with a single instrument, minimizing instrument exchange and allowing a surgeon to focus on their patient and their procedures. With Cool-Coag technology, the new J-Plasma/Renuvion handpieces can deliver three distinctly different energy modalities - further increasing the utility and versatility of the J-Plasma system. J-Plasma has been the subject of ten white papers and has been cited therein for its clinical utility in various surgical procedures.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our J-Plasma product initially received FDA clearance in 2012 and a CE mark in December, 2014, which enables us to sell the product in the European Union. In 2014, we created and trained a direct sales force dedicated to J-Plasma. In 2015, we continued the commercialization process for J-Plasma with a multi-faceted strategy designed to accelerate adoption of the product. This strategy primarily involved deployment of a dedicated sales force, extending and customizing the J-Plasma product line and expanding the surgical specialties in which J-Plasma can become the &#8220;standard of care&#8220; for certain procedures.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By the end of&#160;2017, we had&#160;17&#160;field-based selling professionals and a network of&#160;14&#160;independent manufacturing representatives, resulting in a total sales force of&#160;31. This is a surgery based selling organization with its focus on the use of J-Plasma for surgical procedures, with the primary focus of cosmetic surgery in the US </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From 2015 through&#160;2017, we launched numerous new J-Plasma products in an effort to target new surgical procedures, users, and markets. As a result of our sales, marketing and product development initiatives, we have significantly increased the number of physicians using J-Plasma by expanding usage to include the surgical oncology market and the cosmetic surgery market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In&#160;2017&#160;specifically, we launched an updated version of the Bovie Ultimate generator, and a new J-Plasma handpiece for open surgical procedures. The updated version of the Bovie Ultimate generator and the new handpieces allow for the combination of our trademarked Cool-Coag technology and J-Plasma into one, multiple purpose handpiece. Cool-Coag combines standard monopolar coagulation waveforms with helium to provide three distinct modes to stop bleeding including a high fulguration/spray effect. During the second quarter of 2017, we refocused our U.S. sales team into the cosmetic surgery market. Since that time, we have seen a significant increase in the number of physicians using J-Plasma in the cosmetic surgery market.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to assist us in leveraging J-Plasma&#8217;s precision and effectiveness in multiple surgical specialties, we launched a Medical Advisory Board in 2015 which is currently comprised of surgeons who are recognized leaders in GYN, urology, cardiovascular and cardiothoracic surgery, and the cosmetic surgical specialty. In&#160;2018, we added an additional surgeon to this board further enhancing the cosmetic surgical specialty.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, our J-Plasma commercial strategy in the U.S. will be primarily focused on advancing the usage of Renuvion</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;in the cosmetic surgery market. In our international markets, we will also focus on cosmetic surgery and will continue to focus on the surgical oncology market. Our primary international focus will be on advancing the adoption of J-Plasma in the hospital setting. We believe the majority of our targeted procedures in international markets take place in the hospital surgical suite and believe the sales process is shorter in hospitals in international markets as compared to those in the United States. Also, in 2018, we will initiate a clinical and regulatory strategy to support our market focus, once complete, we will launch a corresponding marketing campaign.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are continuing to make substantial investments in the development and marketing of our J-Plasma technology for the long term benefit of the Company and its stakeholders and this may adversely affect our short term profitability and cash flow, particularly over the next 12 to 24 months. While we believe that these investments have the potential to generate additional revenues and profits in the future, there can be no assurance that J-Plasma will be successful or that such future revenues and profitability will be realized.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Customers</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We primarily sell our J-Plasma products through our direct and independent sales force to physicians, surgical centers and hospitals.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Products</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During&#160;2017, Advanced Energy Products consisted of the J-Plasma line of products and the Plazxact arthroscopic bipolar ablator. The J-Plasma system consists of an electrosurgical generator unit (ESU), a handpiece and a supply of helium gas. Radiofrequency (RF) energy is delivered to the handpiece by the ESU and used to energize an electrode. When helium gas passes over the energized electrode, helium plasma is generated which allows for conduction of the RF energy from the electrode to the patient in the form of a precise helium plasma beam. The energy delivered to the patient via the helium plasma beam is very precise and cooler in temperature in comparison to other surgical energy modalities such as standard RF monopolar energy. The Plazxact arthroscopic bipolar ablator is used to ablate damaged, soft tissue in joint procedures to help improve function or reduce pain. The Plazxact system is designed with a very efficient tip design that allows the ablator to be activated with any standard electrosurgical generator. This eases and shortens the sales cycle for the product by removing the need to sell capital equipment to the hospital.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">J-Plasma Generator</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, we launched the newest version of the Bovie&#160;Ultimate&#8482; generator. The Bovie&#160;Ultimate 2.0 is a high frequency electrosurgical generator that can be used for delivery of RF energy and/or helium gas plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The generator offers users monopolar, bipolar and J-Plasma features in a single generator. It also powers the Cool-Coag technology that has been incorporated into the new Precise Open and Precise FLEX J-Plasma handpieces that were released in December 2017. These 2017 new product releases continue to expand the procedure base for J-Plasma by providing the surgeons with the tools they need to access additional anatomic locations and perform specific procedures.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">J-Plasma Disposable Portfolio</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We offer different hand pieces for open and laparoscopic procedures. The helium-based plasma generated from these devices have been shown to cause less thermal damage to tissue than CO2 laser, argon plasma and RF energy products currently available on the market. The technology has a general indication and can be used for cutting, coagulating and ablating soft tissue. The two primary specialties that are targeted in phase one of the product launch are surgical oncology and cosmetic surgery. The advantages of helium plasma continue to be studied throughout the medical and scientific communities. We believe that surgical applications are just one area of opportunity for this technology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Competition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, we are the only company with helium-based plasma and retractable blade products. However, there are RF based competitors, argon plasma competitors, and CO2 laser competitors for our target market. We believe our competitive position did not change in&#160;2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Securities We May Offer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may offer shares of our common stock, preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, with a total value of up to $25,000,000, from time to time under this prospectus at prices and on terms to be determined at the time of any offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">designation or classification; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">aggregate principal amount or aggregate offering price; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maturity, if applicable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">original issue discount, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">rates and times of payment of interest or dividends, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">redemption, conversion, exercise, exchange or sinking fund terms, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preferences over other classes of our securities, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictive covenants, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voting or other rights, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">important United States federal income tax considerations.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">. We may issue shares of our common stock from time to time. Holders of shares of common stock are entitled to one vote for each share on all matters to be voted on by the shareholders, and do not have cumulative voting rights. Subject to the preferences that may be applicable to any then outstanding shares of preferred stock, holders of shares of common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the Board of Directors in its discretion, from funds legally available therefore. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. Subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock, holders of common stock have no preemptive or other subscription rights, and there are no conversion rights or redemption with respect to such shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</font><font style="font-family:inherit;font-size:10pt;">. We may issue shares of our preferred stock from time to time, in one or more series. The rights, preferences and privileges of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series would be set forth in a Certificate of Designations which would be filed with the Delaware Secretary of State. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt Securities</font><font style="font-family:inherit;font-size:10pt;">. We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The debt securities will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports we file with the SEC.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font><font style="font-family:inherit;font-size:10pt;">. We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and/or warrant certificates that contain the terms of the warrants. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Units</font><font style="font-family:inherit;font-size:10pt;">. We may issue, in one or more series, units consisting of common stock, preferred stock, debt securities and/or warrants for the purchase of common stock, preferred stock and/or debt securities in any combination. In this prospectus, we have summarized certain general features of the units. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of units being offered, as well as the complete unit agreement that contains the terms of the units. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may evidence each series of units by unit certificates that we will issue. Units may be issued under a unit agreement that we enter into with a unit agent. We will indicate the name and address of the unit agent, if applicable, in the prospectus supplement relating to the particular series of units being offered.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4213BD56E3A850889114A8BD87E540DB"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act regarding our business, financial condition, results of operations and prospects. Words such as expects, anticipates, intends, plans, believes, seeks, estimates, and similar expressions or variations of such words are intended to identify forward-looking statements. However, these are not the exclusive means of identifying forward-looking statements. Although forward-looking statements contained in this prospectus reflect our good faith judgment, such statements can only be based on facts and factors currently known to us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Further information about the risks and uncertainties that may impact us are described or incorporated by reference in &#8220;Risk Factors&#8221; below. You should read that section carefully. You should not place undue reliance on forward-looking statements, which speak only as of the date of this prospectus. We undertake no obligation to update publicly any forward-looking statements in order to reflect any event or circumstance occurring after the date of this prospectus or currently unknown facts or conditions or the occurrence of unanticipated events. In addition, our past results are not necessarily indicative of future results, thus, we cannot guarantee future results, levels of activity, performance or achievements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0818874BEA025D88BB27AB10CC939E8F"></a></div><div style="line-height:120%;padding-bottom:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing in our securities involves significant risks. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in, or incorporated into, the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference herein or therein. Each of the referenced risks and uncertainties could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities. Additional risks and uncertainties not known to us or that we believe are immaterial may also adversely affect our business, operating results and financial condition and the value of an investment in our securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><a name="sE845B2C7F1F65375A8925C86544F0F2B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise indicated in the applicable prospectus supplement, we currently intend to use the net proceeds from the sale of securities offered by this prospectus for working capital and other general corporate purposes, including expanding our sales and marketing, capital expenditures, facilities expansion, acquisitions of complementary products, technologies or businesses and repaying indebtedness we may incur from time to time. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business.&#160;As a result, unless otherwise indicated in the prospectus supplement, our management will have broad discretion to allocate the net proceeds of the offerings.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCDA4A8FD1B2053B1BAEF63BB28C863E0"></a></div><div style="line-height:120%;text-align:center;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is only a summary of the material terms of our common stock and preferred stock. Because it is only a summary, it does not contain all the information that may be important to you. Accordingly, you should carefully read the more detailed provisions of our certificate of incorporation, as amended, and our by-laws, each of which has been filed with the SEC, as well as applicable provisions of Delaware law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Authorized Capitalization </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our authorized capital stock consists of 75,000,000 shares of Common Stock, par value $0.001 per share, and 10,000,000 shares of &#8220;blank check&#8221; Preferred Stock, par value $.001 per share. As of April 30, 2018, there were 33,023,049 shares of common stock issued, and 32,879,970 shares outstanding, held by approximately 601 stockholders of record and over 3,500 beneficial owners.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of shares of common stock are entitled to one vote for each share on all matters to be voted on by the stockholders, and do not have cumulative voting rights, subject to the preferences that may be applicable to any then outstanding shares of preferred stock. Holders of shares of common stock are entitled to share ratably in dividends, if any, as may be declared from time to time by the Board of Directors in its discretion, from funds legally available therefore. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to shareholders after the payment of all of our debts and other liabilities. Holders of common stock have no preemptive or other subscription rights, and there are no conversion rights or redemption with respect to such shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our certificate of incorporation, as amended, provides that our Board of Directors has the authority, without further action by the stockholders, to issue up to a specified number of shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of this preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of a series, without further vote or action by the stockholders.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we issue preferred stock, our Board of Directors would fix the rights, preferences, privileges and restrictions of the preferred stock of each series in a Certificate of Designations relating to that series. We will incorporate by reference as an exhibit to the registration statement that includes this prospectus or as an exhibit to a current report on Form&#160;8-K, the form of any Certificate of Designations that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. This description will include:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the title and stated value;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of shares we are offering;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the liquidation preference per share;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the purchase price;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the dividend rate, period and payment date and method of calculation for dividends;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the procedures for any auction and remarketing, if any;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the provisions for a sinking fund, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any listing of the preferred stock on any securities exchange or market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voting rights, if any, of the preferred stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">preemption rights, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on transfer, sale or other assignment, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a discussion of any material or special United States federal income tax considerations applicable to the preferred stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The issuance of preferred stock, whether pursuant to this offering or otherwise, could adversely affect the voting power, conversion or other rights of holders of our common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer Agent and Registrar</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transfer agent and registrar for our common stock is Manhattan Transfer Registrar Co. Its telephone number is 800-786-0362.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Listing</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock trades on the NYSE MKT Market under the symbol &#8220;BVX.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware General Corporation Law Section 203</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a corporation organized under the laws of the State of Delaware, we are subject to Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) which restricts certain business combinations between us and an &#8220;interested stockholder&#8221; (in general, a stockholder owning 15% or more of our outstanding voting stock) or its affiliates or associates for a period of three years following the date on which the stockholder becomes an &#8220;interested stockholder.&#8221; The restrictions do not apply if (i) prior to an interested stockholder becoming such, the board of directors approves either the business combination or the transaction in which the stockholder becomes an interested stockholder, (ii) upon consummation of the transaction in which any person becomes an interested stockholder, such interested stockholder owns at least 85% of our voting stock outstanding at the time the transaction commences (excluding shares owned by certain employee stock ownership plans and persons who are both directors and officers of us) or (iii) on or subsequent to the date an interested stockholder becomes such, the business combination is both approved by the board of directors and authorized at an annual or special meeting of our stockholders, not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock not owned by the interested stockholder.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Limitations of Liability and Disclosure of Commission Position On Indemnification for Securities Act Liabilities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under Delaware law, we have adopted provisions in our certificate of incorporation that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any breach of the director&#8217;s duty of loyalty to us or our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends under DGCL Section 174; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any transaction from which the director derived an improper personal benefit.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our certificate of incorporation also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the company pursuant to the foregoing provisions, or otherwise, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB916402F71B451E383A880E106E0EC1B"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF DEBT SECURITIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue debt securities, secured or unsecured, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. As you read this section, please remember that the specific terms of a debt security as described in the applicable prospectus supplement will supplement and may modify or replace the general terms described in this section. If there are any differences between the applicable prospectus supplement and this prospectus, the applicable prospectus supplement will control. Unless the context requires otherwise, whenever we refer to the indentures, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue the debt securities under an indenture that we would enter into with a trustee to be named in the indenture. If we enter into an indenture, the indenture would be qualified under the Trust Indenture Act of 1939, as in effect on the date of the indenture. We use the term &#8220;trustee&#8221; to refer to the trustee under the indenture.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we issue debt securities, we will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the title or designation of the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the debt securities will be secured or unsecured, and the terms of any secured debt;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of the subordination of any series of subordinated debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any limit upon the aggregate principal amount of the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the date or dates on which the debt securities may be issued and on which we will pay the principal on the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the date or dates interest will be payable and the record dates for interest payment dates or the method for determining such dates;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the manner in which the amounts of payment of principal of, premium or interest on the debt securities will be determined, if these amounts may be determined by reference to an index based on a currency or currencies other than that in which the debt securities are denominated or designated to be payable or by reference to a commodity, commodity index, stock exchange index or financial index;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the currency of denomination of the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the place or places where the principal of, premium, and interest on the debt securities will be payable, where debt securities of any series may be presented for registration of transfer, exchange or conversion, and where notices and demands to or upon us in respect of the debt securities may be made;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the form of consideration in which principal of, premium or interest on the debt securities will be paid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms and conditions upon which we may redeem the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund, amortization or analogous provisions or at the option of a holder of debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the dates on which and the price or prices at which we will repurchase the debt securities at the option of the holders of debt securities and other detailed terms and provisions of these repurchase obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal amount;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the debt securities are to be issued at any original issuance discount and the amount of discount with which such debt securities may be issued;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the debt securities will be issued in the form of certificated debt securities or global debt securities and, in such case, the depositary for such global security or securities and the terms and conditions, if any, upon which interests in such global security or securities may be exchanged in whole or in part for the individual securities represented thereby;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions, if any, for the defeasance of the debt securities of a series in whole or in part and any addition or change in the provisions related to satisfaction and discharge;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the form of the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms and conditions upon which the debt securities will be so convertible or exchangeable into securities or property of another person, if at all, and any additions or changes, if any, to permit or facilitate such conversion or exchange;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the debt securities will be subject to subordination and the terms of such subordination;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provisions, if any, granting special rights to holders of the debt securities upon the occurrence of specified events;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any restriction or condition on the transferability of the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any addition or change in the provisions related to compensation and reimbursement of the trustee which applies to securities of such series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any addition to or change in the events of default described in this prospectus or in the indenture with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any addition to or change in the covenants described in this prospectus or in the indenture with respect to the debt securities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any other terms of the debt securities, which may modify or delete any provision of the indenture.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conversion or Exchange Rights</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we issue debt securities, we will set forth in the prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidation, Merger or Sale</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities, as appropriate. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders of the debt securities additional protection in the event we have a change of control or in the event of a highly leveraged transaction (whether or not such transaction results in a change of control), which could adversely affect holders of debt securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Events of Default Under the Indenture</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we fail to pay interest when due and payable and our failure continues for more than 30 days and the time for payment has not been extended or deferred;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we fail to pay the principal, premium, or sinking fund payment, if any, when due and payable and our failure continues for more than 30 days and the time for payment has not been extended or delayed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if we fail to observe or perform any other covenant relating to such series contained in the debt securities of such series or the indenture, other than a covenant specifically relating to and for the benefit of holders of another series of debt securities, and our failure continues for 60 days after we receive written notice from the trustee or holders of not less than a majority in aggregate principal amount of the outstanding debt securities of the applicable series; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if specified events of bankruptcy, insolvency or reorganization occur as to us; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any other event of default provided in or pursuant to the applicable agreement or indenture, if any, or prospectus supplement with respect to the debt securities of that series.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, no event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of default with respect to any other series of debt securities. The occurrence of an event of default may constitute an event of default under any bank credit agreements we may have in existence from time to time. In addition, the occurrence of certain events of default or an acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than a majority in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) of and premium and accrued and unpaid interest, if any, on all debt securities of that series. The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an event of default.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the terms of the indenture, if an event of default under the indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that, subject to the terms of the indenture, the trustee need not take any action that it believes, upon the advice of counsel, might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A holder of the debt securities of any series will only have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies if:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the holder previously has given written notice to the trustee of a continuing event of default with respect to that series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the holders of at least a majority in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the trustee to institute the proceeding as trustee; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series (or at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) other conflicting directions within 60 days after the notice, request and offer.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will periodically file statements with the applicable trustee regarding our compliance with specified covenants in the applicable indenture.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Modification of Indenture; Waiver</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee and we may, without the consent of any holders, execute a supplemental indenture to change the applicable indenture with respect to specific matters, including, among other things:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to surrender any right or power conferred upon us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to provide, change or eliminate any restrictions on the payment of principal of or premium, if any, on the debt securities; provided that any such action shall not adversely affect the interests of the holders of debt securities of any series in any material respect;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to change or eliminate any of the provisions of the indenture; provided that any such change or elimination shall become effective only when there is no outstanding debt security of any series created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision and as to which such supplemental indenture would apply;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to evidence the succession of another corporation to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to evidence and provide for the acceptance of appointment by a successor trustee with respect to one or more series of debt securities and to add or change provisions of the indenture to facilitate the administration of the trusts thereunder by more than one trustee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to cure any ambiguity, mistake, manifest error, omission, defect or inconsistency in the indenture or to conform the text of any provision in the indenture or in any supplemental indenture to any description thereof in the applicable section of a prospectus, prospectus supplement or other offering document that was intended to be a verbatim recitation of a provision of the indenture or of any supplemental indenture;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to add to or change or eliminate any provision of the indenture as shall be necessary or desirable in accordance with any amendments to the Trust Indenture Act of 1939;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to make any change in any series of debt securities that does not adversely affect in any material respect the interests of the holders of such debt securities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to supplement any of the provisions of the indenture to such extent as shall be necessary to permit or facilitate the defeasance and discharge of any series of debt securities; provided that any such action shall not adversely affect the interests of the holders of debt securities of such series or any other series of debt securities.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">extending the fixed maturity of the series of debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any debt securities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reducing the principal amount of discount securities payable upon acceleration of maturity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">making the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairing the right to institute suit for the enforcement of any payment on or after the fixed maturity date of any series of debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">materially adversely affecting the economic terms of any right to convert or exchange any debt securities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may, on behalf of the holders of all debt securities of that series, waive our compliance with provisions of the indenture. The holders of a majority in principal amount of the outstanding debt securities of any series may, on behalf of the holders of all the debt securities of such series, waive any past default under the indenture with respect to that series and its consequences, other than a default in the payment of the principal of, premium or any interest on any debt security of that series; provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Discharge</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities. In order to exercise our rights to be discharged with respect to a series, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, the premium, if any, and interest on, the debt securities of the series on the dates payments are due.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Form, Exchange and Transfer</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. We may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with a depositary named by us and identified in a prospectus supplement with respect to that series.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange or in the indenture, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we elect to redeem the debt securities of any series, we will not be required to:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Information Concerning the Trustee</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trustee, other than during the occurrence and continuance of an event of default under the indenture, undertakes to perform only those duties as are specifically set forth in the indenture. Upon an event of default under the indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payment and Paying Agents</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will pay principal of and any premium and interest on the debt securities of a particular series at the office of the indenture trustee or, at our option, by wire or check payable to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the trustee our sole paying agent for payments with respect to debt securities of a particular series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the security thereafter may look only to us for payment thereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we otherwise indicate in the applicable prospectus supplement, each indenture and the debt securities will be governed and construed in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="s94E320F608EE536B97726E71975385B5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF WARRANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue warrants to purchase debt securities, preferred stock or common stock. We may issue warrants independently or together with any other securities we offer under a prospectus supplement. The warrants may be attached to or separate from the securities. We may issue each series of warrants under a separate warrant agreement that we will enter into with a bank or trust company, as warrant agent. The statements made in this section relating to the warrant agreement are summaries only. These summaries are not complete. When we issue warrants, we will provide the specific terms of the warrants and the applicable warrant agreement in a prospectus supplement. To the extent the information contained in the prospectus supplement differs from this summary description, you should rely on the information in the prospectus supplement. For more detail, we refer you to the applicable warrant agreement itself, which we will file as an exhibit to, or incorporate by reference in, the registration statement. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will describe in the applicable prospectus supplement the terms relating to warrants being offered including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the offering price and aggregate number of warrants offered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if applicable, the date on and after which the warrants and the related securities will be separately transferable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of any rights to redeem or call the warrants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the dates on which the right to exercise the warrants will commence and expire;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the manner in which the warrant agreements and warrants may be modified;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal income tax consequences of holding or exercising the warrants, if material;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the terms of the securities issuable upon exercise of the warrants; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including, in the case of warrants to purchase common stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up of our affairs or to exercise voting rights, if any.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise of Warrants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of the warrants may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We intend to set forth in any warrant agreement and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon receipt of the required payment and any warrant certificate or other form required for exercise properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant or warrant certificate are exercised, then we will issue a new warrant or warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governing Law </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of Delaware. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE0BCA20F6B205AB389ABAA94FBD8F0A1"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF UNITS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue units comprised of one or more debt securities, shares of common stock, preferred stock and/or warrants in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The statements made in this section relating to the unit agreement are summaries only. These summaries are not complete. When we issue units, we will provide the specific terms of the units and the applicable unit agreement in a prospectus supplement. To the extent the information contained in the prospectus supplement differs from this summary description, you should rely on the information in the prospectus supplement. For more detail, we refer you to the applicable unit agreement itself, which we will file as an exhibit to, or incorporate by reference in, the registration statement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will describe in the applicable prospectus supplement the terms of the series of units being offered, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any provisions of the governing unit agreement that differ from those described below; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provisions described in this section, as well as those described under &#8220;Description of Capital Stock,&#8221; &#8220;Description of Debt Securities&#8221; and &#8220;Description of Warrants&#8221; will apply to each unit and to any common stock, debt security or warrant included in each unit, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may issue units in such amounts and in such numerous distinct series as we determine.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9FFF09CBC8935303B7406969B2798F1E"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may sell the securities through underwriters or dealers, through agents, or directly to one or more purchasers. We may sell the securities from time to time in one or more transactions at a fixed price or prices, which may be changed from time to time, at market prices prevailing at the times of sale, at prices related to such prevailing market prices, or at negotiated prices. The accompanying prospectus supplement will describe the terms of the offering of the securities, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the name or names of any underwriters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the purchase price of the securities being offered and the proceeds we will receive from the sale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any over-allotment options pursuant to which underwriters may purchase additional securities from us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any public offering price;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any discounts or concessions allowed or reallowed or paid to dealers; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any securities exchange or market on which the securities may be listed.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of the sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe such relationships in the prospectus supplement naming the underwriter and the nature of any such relationship.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may engage in &#8220;at the market&#8221; offerings of our common stock in accordance with Rule 415 under the Securities Act, which are offerings into an existing trading market, at other than a fixed price, on or through the facilities of a national securities exchange or to or through a market maker otherwise than on an exchange.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of the securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best efforts basis for the period of its appointment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of common shares, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of common shares. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be identified in the applicable prospectus supplement or a post-effective amendment to this registration statement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some or all of the securities that we offer through this prospectus, other than common stock, may be new issues of securities with no established trading market. Any underwriters to whom we sell our securities for public offerings and sale may make a market for those securities, but they will not be obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity of, or continued trading markets for, any securities that we offer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All securities we offer, other than common stock, will be new issues of securities for which there is no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making activities at any time without notice. We cannot guaranty the liquidity of the trading markets for any securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any underwriter may also engage in stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule&#160;104 under the Securities Exchange Act of 1934, as amended.&#160;Stabilizing transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing or maintaining the price of the securities.&#160;&#160;Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions.&#160;&#160;Stabilizing transactions, syndicate covering transactions and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions.&#160;The underwriters may, if they commence these transactions, discontinue them at any time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Similar to other purchase transactions, an underwriter&#8217;s purchases to cover the syndicate short sales or to stabilize the market price of our securities may have the effect of raising or maintaining the market price of our securities or preventing or mitigating a decline in the market price of our securities. As a result, the price of the securities may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of shares if it discourages resales of the securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any underwriters who are qualified market makers on the NYSE MKT Market may engage in passive market making transactions in our common stock on the NYSE MKT Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underwriters, broker-dealers or agents who may become involved in the sale of our securities may engage in transactions with and perform other services for us in the ordinary course of their business for which they receive compensation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s53B51017ABD25A88B669B0A71071C352"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL MATTERS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The validity of the issuance of securities offered hereby will be passed upon for us by Ruskin Moscou Faltischek, P.C., of Uniondale, New York.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFF2AD47012B95FF595A8D49701155F54"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPERTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements incorporated in this prospectus by reference from Bovie Medical Corporation&#8217;s Annual Report on Form l0-K for the year ended December 31, 2017 have been audited by Frazier and Deeter, LLC, independent auditors, as stated in their report, which is incorporated herein by reference, and have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8C428EEFB3335E6194C53C5C32DC1725"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at www.sec.gov. You may also read and copy any document we file at the SEC&#8217;s public reference room at 100 F Street, N.E., Washington, D.C. 205409. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registration statement and the documents referred to below under &#8220;Incorporation of Certain Information by Reference&#8221; are also available on our website at http://www.boviemedical.com. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0C1B50EB84885319BA79DE2D481082AA"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SEC allows us to incorporate by reference the information we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c) 14 or 15(d) of the Securities Exchange Act of 1934, as amended, until this offering is completed and all securities are sold or until the sale of securities pursuant to this prospectus is terminated by us:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 13, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2018 filed with the SEC on May 15, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Current Reports on Form 8-K filed with the SEC on March 14, 2018, May 3, 2018 and May 14, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description of the Registrant&#8217;s Common Stock contained in the Registration Statement on Form 8-A filed with the SEC on November 3, 2003.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This prospectus is part of a registration statement on Form S-3 we have filed with the SEC. This prospectus does not contain all of the information in the registration statement. We have omitted certain parts of the registration statement as permitted under the rules and regulations of the SEC. You may view and inspect the registration statement and exhibits at the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 205409 by calling 1-800-SEC-0330 or on the SEC&#8217;s website (see above &#8220;Where You Can Find Additional Information&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon request, Bovie will provide, free of charge, to each person to whom a prospectus is delivered, including a beneficial owner, a copy of any or all information that has been incorporated by reference in the prospectus but not delivered with the prospectus. Any such request may be made orally or in writing to Bovie Medical Corporation, 5115 Ulmerton Road, Clearwater, Florida 33760, Attention: Jay D. Ewers, Chief Financial Officer, Tel. No.: (727) 803-8636.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="sFF9C892453035BA7ACC6893895DE7B1C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="a2017bvxlogoa03.jpg" alt="a2017bvxlogoa03.jpg" style="height:84px;width:285px;"></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">$25,000,000</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Debt Securities</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Units</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BOVIE MEDICAL CORPORATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PROSPECTUS</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">May&#160;16, 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="s20E653FAC574559F81BFA03636BE4DB7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">II</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the estimated costs and expenses of the sales and distribution of the securities being registered, all of which are being borne by us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SEC registration fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,112.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounting fees and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">* The amount of securities and number of offerings are indeterminable and expenses cannot be estimated at this time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEMNIFICATION OF DIRECTORS AND OFFICERS.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section 145 of the Delaware General Corporation Law (&#8220;DGCL&#8221;) states:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) A corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action arising by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person&#8217;s conduct was unlawful.</font></div><div style="line-height:120%;text-align:justify;text-indent:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:28px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) A corporation shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expense which the Court of Chancery or such other court shall deem proper.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As permitted under the DGCL, we have adopted provisions in our Certificate of Incorporation, as amended, and By-laws that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any breach of the director&#8217;s duty of loyalty to us or our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends under DGCL Section 174; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:72px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any transaction from which the director derived an improper personal benefit.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our Certificate of Incorporation, as amended, also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the company pursuant to the foregoing provisions, or otherwise, we have been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16. EXHIBITS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following documents are filed as part of this Registration Statement:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Underwriting Agreement</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Articles of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</font></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">By laws of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q3exhibit35.htm"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 3, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx_201805xex31certificate.htm"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Certificate of Elimination (Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on May 3, 2018)</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000024/bvx_201805xex45formofinden.htm"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">Form of Indenture</font></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.6*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Common Stock Warrant Agreement and Warrant Certificate</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Preferred Stock Warrant Agreement and Warrant Certificate</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Unit Agreement</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Opinion of Ruskin Moscou Faltischek, P.C.</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1**</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent of Ruskin Moscou Faltischek, P.C. (contained in Exhibit 5.1)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.2**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent of Frazier &amp; Deeter, LLC</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">*   </font><font style="font-family:inherit;font-size:9pt;">To be filed by amendment or by a report filed under the Securities Exchange Act of 1934, as amended, and incorporated herein by reference, if applicable.</font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">** Previously filed.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 17. UNDERTAKINGS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The undersigned registrant hereby undertakes:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(1)</font><font style="font-family:inherit;font-size:10pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:10pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement.</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:10pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provided, however</font><font style="font-family:inherit;font-size:10pt;">, that:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(A) Paragraphs (i), (ii)&#160;and (iii)&#160;above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement; and</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(2)</font><font style="font-family:inherit;font-size:10pt;">That, for the purpose of determining any liability under the&#160;Securities Act&#160;of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. &#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(3)</font><font style="font-family:inherit;font-size:10pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(4)</font><font style="font-family:inherit;font-size:10pt;">For the purpose of determining liability under the Securities Act of 1933 to any purchaser:</font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:10pt;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&#160;for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(5)</font><font style="font-family:inherit;font-size:10pt;">For the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font></div><div style="line-height:120%;text-align:justify;padding-left:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:96px;text-align:justify;text-indent:0px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6) For purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">annual report pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7)&#160;&#160;&#160;&#160;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, and will be governed by the final adjudication of such issue.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8) That, for purposes of determining any liability under the Securities Act of 1933:</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) &#160;&#160;&#160;&#160;The information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and</font></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) &#160;&#160;&#160;&#160;Each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9) To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a)&#160;of Section&#160;310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the SEC under Section&#160;305(b)(2) of the Act.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="s94C512F16B4F5930A2F63D0E9279F763"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Clearwater, State of Florida on </font><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:48%;"></td><td style="width:5%;"></td><td style="width:34%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Bovie Medical Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Charles D. Goodwin II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles D. Goodwin II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each person whose signature appears below hereby constitutes and appoints Charles D. Goodwin II as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Directors:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ CHARLES D. GOODWIN II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer and Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charles D. Goodwin II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ ANDREW MAKRIDES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman of the Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Andrew Makrides</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ JAY D. EWERS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer), Treasurer and Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay D. Ewers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ J. ROBERT SARON</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Sales and Marketing Officer and Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">J. Robert Saron</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ JOHN ANDRES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice Chairman of the Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John Andres</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ LAWRENCE J. WALDMAN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lawrence J. Waldman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ MICHAEL GERAGHTY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Geraghty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ CRAIG A. SWANDAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;16, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig A. Swandal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>a2017bvxlogoa03.jpg
<DESCRIPTION>BVX LOGO
<TEXT>
begin 644 a2017bvxlogoa03.jpg
M_]C_X1"J17AI9@  34T *@    @ # $   ,    ! LP   $!  ,    ! -(
M  $"  ,    $    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q  (
M   D    M@$R  (    4    VH=I  0    !    \    2@ "  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0T,@,C Q-2 H36%C:6YT
M;W-H*0 R,#$U.C Y.C(Y(#$R.C,P.C,Q      20   '    !# R,C&@ 0 #
M     ?__  "@ @ $     0   LR@ P $     0   -(         !@$#  ,
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MQ?\ P]7_ .>LE<]]0_KGT?ZN],R<7/%SK;L@VM])FX;?3JKU=O;[MU;UT/\
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M#P   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
M  !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET
M8F]O;      +<')I;G1E<DYA;65415A4    %@!% %  4P!/ $X ( !3 '0
M>0!L '4 <P @ %  <@!O "  ,P X #  ,       #W!R:6YT4')O;V93971U
M<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T
M=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--
M64L .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO
M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M 2P    !  $!+     $  3A"24T$)@      #@             _@   .$))
M300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #:0    8              -(   +,
M&@!" $\ 5@!) $4 7P!# &\ ; !O '( 7P!( &D 9P!H %( 90!S &\ ; !U
M '0 :0!O &X    !                          $              LP
M  #2                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  #2     %)G:'1L;VYG   "S     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M<@(9?:A6O#&\DC_?E\KS Q/KMF ^MDUX;"?H M! _DFAECO_  9&K^JV<_\
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M &\ <    !< 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# $,
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MJ+7]EL'9-)Y-/D^VVK@J?R:-6C7XJ!->G4;7^ES[1/N^[24\3<[AJ<*R.?\
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M7N_7BF[A7 ^' JIS7WM+U/S-^2]65:7M"L0J"!]MMS9M&"#_ *I:/;L"N?\
M$@GVM3V^Y/2M-F7\Y)3_ (9#T"[W^\/^^1?LCS^]5PI44'AV&TPC\Q%8(&/S
M()\N'7O:>F^4_P AIUE5^V=VJ)0P8PU4%,RZKW\34U/$T)YXT%;?BWM4O)?*
MJD$;'!CU!/\ A.?SZ"=S]]S[V-TDT<OOMOP$E:Z)4C(KQTF.-2GRT%:>5.O>
MVO\ V9#OO_G[_8'_ *$N2_Z_>W_ZI<L?]&&U_P"<:_YNB7_@OOO1_P#A?>:_
M^YC<?]!]>]M7^G?O#_G\O:W_ *,/=W_UX]O?U:Y<_P"F?LO^<$7_ $#T1_\
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M_8Q[]_PRQ_+!_P"\3=J?^AGVK_\ 9Y[]_P &;]YK_P *M=_]D]C_ -LO7O\
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M8\<\?>V^[5[<BX7FSWIV&*YBKKA@N!>W"TP0;:R%S< X^'P]1]#U[V6[=/\
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M:+):50'[V3(_Q"/R%26=_P"'5]/RUFTV'T ]XU>YT<B<UW#/\+PQE?LTZ?\
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M_P">>P?_ )Z:#_ZG]^_OYOG_ )[/=?\ Z$67_P#JSW[]Q;)_T9K3_G#'_P!
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M'I ;IZ#Z/WNTTF[^G^LMR5%28C/69C9&VZVOD,*TZ1WR$V-:M&F.EC3B071
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M\T'_ +Q.W+_Z'G47_P!L'W[_ (,W[LO_ (5>T_[)[[_MEZ]_K'>ZO_3'3_\
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M'3_\Y(/^MO1=_P#APKX:?\_VVY_YY]W?_8[[]_PRC_-!_P"\3MR_^AYU%_\
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M8[W"'WE?_$?O>3_Q7;[_ *L/T/O:S_IY'(__ $L[?_JX.BU_,?\ [)3^0O\
MXB/>_P#[HZOW]./W\T/75+K33]^]^Z]U[W[W[KW7O?SF/YXO_;TSY5_]K+JC
M_P!\3U=[^B+[DG_B+WM9_P T[[_NYWO7,[WZ_P"GM<W?Z>W_ .T2#K;=_EM_
M]D4='_\ 4%O;_P!^7O/W4_[RKZB#H\?OWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>_>_=>Z][][]U[KWOZ,W\DKH^KZ,_EQ=$8_,8FIPVYNQX=P]P[BI:Q$BJ9'
MW]F:BKVM4RPQU-2(3-U]28>R,4D '[D<<FN-?G>^^KSM#SQ]XKGFXL[I)MMV
MXQ;?$RFH'TL86< T6M+IKC(J/X69:,>F'L1L+[![9;!'/"4NKH/<N#@_JL3&
M:5-*PB/Y^H!J!J3?S'NR:?LOY<]EU./K:>OP^SVQ.P,5/3.9(0NV*".+-1+(
MT47D,>Z:FO!(#)?]+.MF-L/O%/J8.B,>_>_=>Z][I0_X4"=JTG7/\MGL?;KR
M%,IW)O?K;K+#:6H2PDCW/3=AY=WAK)4DEADV[L&K@)@26:-YT8!5#2)FC]P3
ME67F+[QW+NXA:VNSV-Y>2?%YPFTCRHH");I&[B%(4BI)"F"OO&;NFV>V&YVQ
M/ZM]/! O#^,3-@\1HB88!(J#\Q8S_*PV//NWY?;2RX371=?;;W?O&NNM0%.O
M#R[4QZ^6!&6.1<IN>&4"1D1Q$5N20K?/G]]_.N<G6U/[][]U[KWOWOW7NO>_
M>_=>Z][][]U[KWOWOW7NO>UQUSUMO_M[>>$Z[ZOV?N#?F^=R5#TF"VMM?&U&
M6S.3FCADJ)EIJ.E1Y"D%/"\DCFR1QJ68@ GV2\P\Q[#RGL][S!S-N]O8[';+
MJEGF<1QH"0!J9C3)( '$F@&>EVV[9N&\7L&W;5927%_*:)'&I9F/R ^6?EQZ
M3NZMV;8V-@,CNG>.>Q6VMN8B$5&2S6:K(:''44.H('GJ:ADC0%V '-R3Q[VL
MO@Y_PFZA\&%[ ^<F[95J&:DR$71?762A/B55QM6*+?F_8!/!Y!4)4TU51843
M))3LDD>1CD+1IRR][O[QHA[S8/9':0R94[E=H:'XQJMK4T:E"C))<:2K@JUN
MRT8Y=<A?=BJL&X\_7A!P?I86%?(TEE%1Q!!6/552")%-0*1/DE_-Y6.3(;6^
M-F!CJ5 EIG[)W923QP,6$\33[;VQ)X*J0>*2.2*HKS 8YD(-+(EF;9PZ-^-O
M0OQHVK#LSH;J?9/5VWXZ>FIZB':V&IZ7)9?[1/'!4[CW!,)]P;HR07]57D:J
MJJI"26D8DGWS/YX]R.?/<K='WCGOFN]W2^+$@S2$I'JXB&(4BA7^A"B(/)1U
ME3R_RMR[RK:"RY>V:"TMZ 'PU 9J<"[FKR'^D[,?GU3/V9W)VGW+F7SW:&^]
MQ[TR)EDFA_C.0DDH*!I0JR)B,/#X<1AH&"C]JD@ACX_3[&WV">C_ *#3W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]@9WK\9N@/DUME]H]]]2;([1PI
MIZFEI1N?#0SY;#I6!142[<W)3?;;CVQ62:%/W&.JZ6=64$." 0.>1O<SG_VS
MW(;KR'S;>[7>:@S>#(1'(5X>+"VJ&8"I[98W7)QT'^8.5.7.:K4V?,6S07<-
M"!K7N6O'0XHZ'YHRGY]"?UCW3VMTQEAF^KM^[DV77>9)YTQ%>XQM?)$K)'_%
ML+4BHPV8C1'("55/,EC]/>L!\Y/^$W=71T^;[!^#F[YLKIDGR$O1O8U?34]<
ML329&LJ:;8^_%B@HJUD,U/346/RD%*8X829<C/*_OIO[(?WC,$\EEL'O;M"P
MD@(-RM%8I6BJIN;8DLG!FDEA:2K-VP1H.L4>?ONQ21+/N7(5Z9!DFUF(#4R2
M(I<*W$!4<+0#,C,>KHOC7_-WHJZ;';5^2.!BQ+NL=)'V/M.GGFQS2!888)-Q
M;;>2:LH5(C9YZJDEJ0\LMQ3PQK[U7=_]>;ZZJW=F=@]E;1W!L7>NWJ@4F<VM
MNC%U6&S>*J6C658JW'UL<51 [1R!A<<@W'OJ-L/,&Q\T;39[[RYNT%]LUPNJ
M*:%UDC=?574D$=8E;AMU_M-Y/M^YVDEO?1&CQNI5E/H0:$=78[9W1MS>F#Q^
MYMI9S%[CV]EH!4XW-8:L@K\;74[7M-35=.[PS1M^""1^?:,]F_2+I^]^]^Z]
MU[W[W[KW7O>VM_PEE_XN7SA_Z@OCE_UO[S]\G_[T/_<;V2_YJ;O_ (-MZS$^
MZ7_:\^_Z6R_PW75%7\[#_@#\;_\ J+[9_P"M/7'O;Q]\DNLS.J%/?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?R3]P?\7_.?]K?)?\ N;-[
M^L';_P#<"Q_YHI_QT=<=;G_<B?\ T[?X3UO8XK_BUXW_ *@*/_W'C]M'M9TS
MU/\ ?O?NO=>][2?_  EW_P"9T_*S_P 1?L#_ -ZO+>^8?]YS_P J/[7_ /2U
MN?\ M'7K*_[J/_*P\V?\\<?_ %</5,'\Z'_F573/_B0<U_[SDGO<T]\;NLX>
MM=[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W\J'Y(_]E$]
M]_\ B:>TO_>YSOOZGO;[_E0N2/\ I46?_:/'UR(YC_Y6'??^>V?_ *NMUO$]
M9_\ ,M^OO_#(VI_[H:#W<[_PFQ_[>#;G_P#%:^QO_>TZP]X;_P!XW_XC]8_^
M+%9_]6+OJ</NQ?\ 3R9O^E;/_P ?AZKQ_F[?]DGTO_B5=G?^ZS<_O?!]\*>N
M@_6L)[][]U[KWOWOW7NO>_>_=>Z][][]U[KWNCW_ (4,_P#;M7>__B4.IO\
MWI?>;W]WO_XD=M7_ $JK[_JVO4!?>4_Z=A=?\]EO_P >/5F/\IC_ +*[QO\
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M5 55  %O>%TDDDTDDTTC/*[$LQ))))J22<DDY).2>IU1$C1410J*   *  <
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MC=XW1W*#[EOH&]#O[][]U[KWO;6_X2R_\7+YP_\ 4%\<O^M_>?OD_P#WH?\
MN-[)?\U-W_P;;UF)]TO^UY]_TME_ANNJ*OYV'_ 'XW_]1?;/_6GKCWMX^^27
M69G5"GOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOY)^X/\
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M]P]\_P#/&;K_ /0=R_\ ]1^\I?W[LG_1YM/^<T?_ $%U$?[NW#_E!F_WAO\
M-T=S^\^VO^>AP?\ Y]J#_P"J/?O[A[Y_YXS=?_H.Y?\ ^H_?OW[LG_1YM/\
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M+-,WDJ:AM(9FTK87L/?TB[#L>U\L[)M/+NR6B0;18V\<$,:@!4CB4(B@* ,
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M$!A'">#4&5ZQLW[[UF\2NT?+7+5O!#D![AFE<\:'1&8U4\#0LX\OGU;'UO\
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MK6%/-5U=0UR5CB6."FIX4"QPP1(D,$*+'&BQJJA9>R;I=TG/?O?NO=>]E?\
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M0/M'_P!-9_V:WO\ VS]+W_ALOYN_\^4'_HR.I/\ [//?O^'V_P"55_WE*?\
MT2'R,_\ M1>_?\ S]Z7_ ,)?_P!U+:/^V_KW_! ^T?\ TUG_ &:WO_;/U[_A
MLOYN_P#/E!_Z,CJ3_P"SSW[_ (?;_E5?]Y2G_P!$A\C/_M1>_?\  ,_>E_\
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MT4L%705&WMHQ9+(0U".C)4TT2JP=T]Y.?=!]L3[H^^W*&VW,(;9=ND_>%U4
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M<\8=EAK:*9E055#5!"8Y .>58*ZLH%/V%NC?I#>_>_=>Z][)[\[/B#LGYO\
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M=C[,AIC3X&NRAW?M$B(0T[[:W2SY.D@HT\L[?:XBLDJ,>I9BQ-&;\^S_ 'N
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MO#SWSLDI;;KF]9+7CBT@I#;<>&J)%=A_$S==5?;;E<<G<D<O;"R4NHX TO\
MS6D[Y?V.Q4?(#K3.^67<#=Z_(3L[L:*H:?#Y+<-1CMKGR-(B[4P(7#[?>+6
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M[?\ [/O?O^@:;X _\]U\H?\ T8?77_VH/?O^3D?OW_T8^6/^R2[_ .V_KW_
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M!M*K>G:*')_&OKVHAGL"E4U/O;L^BE(8$CR0FG"LILP4*;692>Z7]W%<I-[
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MG3>7#]0X)ZNA,C!(WW;NB*KQ.**JP/W(H<4E=,0/\U+X6)!*AM$3WW-ZY_\
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M%LUONL_=/VC[QFP<U;K=<\S[5>;9>1Q&-+9+@.DL>M7J9XF4ZE=::2#3!J&
M@;W=]XK[VQW+:+.#8([N"Z@9]32M&59'TE<(P(H5/$$5R.'5DWP@^".W/EUL
M_>NX<CV5EME9#9^Y*/#-CZ#;U!FXJNCR&+CKJ6L9Y\OCYZ>0SQSI8J48(+&X
M8"J?_H*4WC_WACMK_P!'EE/_ +5OO*;_ )-@;'_X6&[_ .Y='_VV=1'_ ,%E
MN7_3%0?]E+?]:>CN_P##*VT?^?\ NX__ $ L9_\ 9-[]_P!!2F\/^\,=M?\
MH\LI_P#:M]^_Y-@;'_X6&[_[ET?_ &V=>_X++<?^F*@_[*6_ZT]>_P"&5MH_
M\_\ =Q_^@%C/_LF]^_Z"E-X?]X8[:_\ 1Y93_P"U;[]_R; V/_PL-W_W+H_^
MVSKW_!9;C_TQ4'_92W_6GKW_  RMM'_G_NX__0"QG_V3>_?]!2F\/^\,=M?^
MCRRG_P!JWW[_ )-@;'_X6&[_ .Y='_VV=>_X++<?^F*@_P"REO\ K3U[_AE;
M:/\ S_W<?_H!8S_[)O?O^@I3>/\ WACMK_T>64_^U;[]_P FP-C_ /"PW?\
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MC_\ 0"QG_P!DWOW_ $%*;P_[PQVU_P"CRRG_ -JWW[_DV!L?_A8;O_N71_\
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MO=CW:Y'Y%6-FM+R]4W!&--K"#-<G51@I\&-U4E2-944-:$%^X?,Z<G<F;_S
M6 GA@(BKYS/V18J*@.RD@$'2#D<>A^^+G4$_>W??6O6:PR38[-[A@JMQE-:B
M+:V%1\SN-FG6*84SS8FAEABD96432("#>Q^7YD*^LRU?6Y3)5,M;D<E5U-?7
MUE0YDGJZVLF>HJJF>0\O-//(S,?RQ]_39!!#:P0VUO&$MXT"JHX*JBB@?(
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MO3/E7_VLNJ/_ 'Q/5_OZ(_N2?^(O>UG_ #3OO^[G>]<SO?K_ *>US=_I[?\
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ML D--31W*4M!14Z+#3P):.&%%10%4#V)7L-]&O2-]^]^Z]U[V0G^9'\U=O\
MP4^+6^.WZF:CJ-_5]+4;3Z?V[51M4KG>QLO1U"X6:LI([.^ V\4-?D68QQF"
M#P"19IX0T\_=P]E[_P!\O=#9.4T1UY?C83[A*N/#M(V'B*K'A+-_91 58,QD
MTE8WI'?NCSU;^W_*5_O!93N3@QVR'.J9@=)(_@3XW\J +4%AT:;X>?'+*?)G
MNO;FQUAJ8]HT$\.=[ RL.J-:#:M%.CUE)%4ZXQ'E,W;[6E"L9 SM*%9(9+?-
M(W%N#,[LSV:W/N+)5N8SVX,G6YC,93)5E5D*_(9+(5$E55U=975TU3654\TT
MI9I)9'D8FY8FY]_21M]A9[78V>VV%ND5C!&L<:(JJJH@"JJJH"@ #   'H.N
M7-S<37=Q-=7$C/<2,69B22234DDDDU]22?7K<+Q>,H<-CJ'$XRF@H\?C:2GH
MJ.EIH(J>G@IJ>-8H8HH*>.*"%$1;!455']/;+[6=,]3_ '[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>][H'_  F?^4)W9U%V]\4MQ98U&:ZNS<79NP*2
MJK)9JH["W:]/B]S4%#32W$.,VYNZ&"=O&Q42YRQ5;@OQN_O*/;$;5S5RA[J[
M?:Z;/<X3973*H"_4P:I(&8CB\T!=<YTVV"<@9O\ W6N:S=[1O7*%S-6:U<3P
M@DD^%)19 *\%20*<><O#UUZOYQO3"X;>G7W>6)HO%0;NH)-D;HFBBACA_O%A
MA49+!U,QC"R2UF4PLE1&S/SHQZV)Y VA_?,/K+'JE3W[W[KW7O>N?_PH4^*&
M0[_V?\.]Q[5@E;=W^S&8+H(2QT[/ F+[X:FI*'(9*IAHJR>CI,1N/:M,BR$K
M /OGUAW,2^^B?]WW[J6_(>[>[^V;K(!M/]7I-TR?Q[94NJ@LH9I(IV-,L?#%
M*#4>L9/O)<H2<PV?)5Y9I6]_>2VG#RNJ:230T"O&,\.\UJ:=6[?RG^[Z3K3-
M]_8'.5'CP*]6U_::B24+'%4]<>4Y%(86G@6:HK\7FKD"[D4H TC4?>P7LS:6
M!V!L_:FQ-K4,6+VQLK;6"VEMS&0"T&.P.V\72X;$4,()-HJ3'T4<:C^B^^?V
M];O?\P;QNV_;I,9-SO;F6XF<\7EF=I)&/S9V)_/K)"PLK?;;&RVZT33:6\21
MH/1$4*H_( #JJ3<NX,GNW<>?W5FYS59G<V;RNX,O5$ &IR>9KI\C7SD#@&:J
MJ7;_ &/M2^RWI7TR>XU;64N.HZO(5T\=+14--/65E5,P2&FI:6)YZB>5SPL<
M,*%F/X ]NP037,\-M;QEYY'"JHR69C0 #U)( ZI)(D,<DLKA8E4DD\  *DGY
M =2*2DJ:^KI:&B@DJ:RMJ(:2DIH5+S5%34R+#!!$@Y>265PJC\D^_F!_/GY(
MU'RU^7O>?>YGFFPN[]Z5M-LN.>%()J38.W4BV[LBCFCCFJ4^XBVSBZ8S.&M)
M,SN @(1?IL]B/;F/VH]I>2.11&HO+.R4W!!)#74M9;EA4#!F=Z"F%H*FE3RE
M]P>9WYQYRW_F$L3#/.?#!I41)V1#%<A%6I\S4_+K= ^,G4<'1?1/6W621Q)6
M[=VY3'/20&0Q56Y<D7RFXZQ/,JR(E5F:N9U4CT+87-KDGON7.@9T/'OWOW7N
MO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][W3/^
M$OW_ &3M\F?_ !-.W?\ WAJ/WQJ_O./^5]]LO^E1/_VD=9P_=1_Y5[FS_GMC
M_P"K76O1_.D_YF1TE_X9&Y?_ '?4OO9[]\Q^LK^J5O?O?NO=>]T>_P#"AG_M
MVKO?_P 2AU-_[TOO-[^[W_\ $CMJ_P"E5??]6UZ@+[RG_3L+K_GLM_\ CQZL
MQ_E,?]E=XW_Q'V]O^M%![^?U[[W]<[.MH_W[W[KW7O?O?NO=>]^]^Z]U[V];
M=W!F=IY["[GV[DJW#Y[;^3HLQA\IC:RJQ]?C\ECZB.JI*NCKJ&:FK*6>&:(,
MLD4B2*1<,#8^T>X6%GNEC>;;?VZ2V,\;1R(ZJRLC@JRLK J00<@@@^AZ>MKB
M:TN(;JWD9+B-@RL"000:@@@@BGJ"#Z=0,IC*',XZNQ.3IH*S'Y*DJ**LI:F"
M*HIYZ:HC:*:*6"HCE@F1T:Q5U93_ $]_3._EX?,3;OSA^*_77=F.J*--V24"
M[8[4P=-''2-M_LO;\45)N6%<<M77-C\7F9=&3QT;32L,=6PAG+A[?-9]X7V?
MW#V2]TN8>3+B)_W1K\>QD)+>+9RDM"==%U/$*PRG2M98W(4*5KU,]M.=K;GW
ME';=\C<?6Z?#N%&-$Z !\9HKXD05-%8"I(/6G+\MOC[E?C9W=NOKVH@G_NZ]
M2V<V-D96:9,EM'*2//BU^[94-368D%J*J8JC-44[/H576YW_ '"/0^Z+1[][
M]U[KWL+NZ.F.M_D'UCN[I[MO;-%N[8.]\8^+SN&K01J4.D])74-2EIJ#*XNM
MBCJ*6IB*R03QJZFX]BCDOG/F3V^YGVGF_E/<GM-^LI-<<B_91D9>#(ZDJZ'#
M*2.BC?MBVOF7:;W9-YM1-MTZZ64_M# ^3*:%2.!'2YZV[(WAU)O7 ]@[#R\V
M$W/MVK%505D7JCD5E:*IHJR D)54%=3NT4T3<.C'Z&Q'SW?YEG\K#N3^7_OM
MZW[7)[_Z!W+6S)L;MC'8N84E/*(7K'VMO2"GDK%VWN2DIXY&B$TGAKX(7EIW
M<QSI%] ?W;_O0\F^_FQ+"LL=ASY;1@W-B[C4173XUN2%\:%B0"5&J-F59%74
MA;G![H>TN^>W6X%VC:XY>E;]*X533A71(*GPW K0$T8 E2:&FUC\0OFMUW\I
M=LI%#4TFV>S<331ON78E96QFL"^5:?\ BV#DE2F.9Q$TTB!GB35 \B+(B%D!
MJK]Y1=1+T=;W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]NF&PV6W%EL
M;@<#C:W,9O,5M/CL7B\=3RU=?D*^KE6&FI*2FA5Y9JB:5PJJHN3[37EY:[?:
MW%]?7"16<2%W=R%5545+,3@ #IR&&6XEC@@C9YG8!5 J23P '42NKJ/%T=3D
M,A4P45#1025-75U,BQ04\$2EI)99&(5451[V>_Y;/_"?/>&_:C#=O?.K&Y'8
MNQ!_"LM@>BH:JHQV_MUPO''D#'V%/3/!6; Q;,8X)\>&&:D4SQN,?(L4S<S?
MO'_?^V;88KSE'V.N8[_?:.DFYE0]K :E:VH-5NI *LLO^XX.A@9UUQ]95^U_
MW<K_ '%X-YY^B:VV[M9;6I6:0<?U:4,*\ 5_M2-0I&=+=4S_ "__ )J6V]J0
M9'8?QJK:/=6ZF2KHLAV28H:S:F D+/3:]M+(LE/NJO1 TL50+XY&,3ZJD"2'
MV0_^=I\ :;X5_)M]R==8"/#_ !_[QAJMT==TM%'308O:>X:5D3>G7='3PK$T
M-)@JF:&LHE$>A,=D((M;R12-[G3[EOOW)[T>V8V_F&_,W/VR$079:I>>(YM[
MMB2:F50R2&HK-%(P5591U'WOK[=)R+S4;C;;?1RY?@R0 4TQN/[6$<,(:,O&
MB.H))!Z,[_+J^4DWR,Z93'[KR?WW:?74D6#WC),6-7FL?*&?;^ZYB9);R9>G
M1X9V] :LI9F5%0J/=,'O,?J$>K!O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_
M_]73C_X;,_F$_P#>&7R._P#15;L_^MWN$/\ @E?N_?\ A9.7?^RZ#_H/H??Z
MUGN1_P!,/N?_ &3R?YNMV3_9Q_BG_P!Y"]1_^AO@_P#ZK]^_X;,_F$_]X9?(
M[_T56[/_ *W>_?\ !*_=^_\ "R<N_P#9=!_T'U[_ %K/<C_IA]S_ .R>3_-U
M[_9Q_BG_ -Y"]1_^AO@__JOV;[X ? #YO==?-[XH;ZWU\4.^]K;.VMWWUCF-
MR;DS'6.ZJ3$8+$4FZL<U9E<K6-CO%18ZBBO)//(5BAB4NY5%9A$?OY[^>RG,
M7LI[J['L?NKL-UO%UL-['##'>P-)+(T#Z41==6=CA5&6-%4$D C3VZ]NN?-L
MY\Y0W#<.4-QALH=Q@9W:"0*BB1:LQTX XDG %232IZ 3Y3?*;XW[M^-_>.V=
ML]X]7YO<&;ZOWGC\1B,?O/"3U^3KY\)5K3T-#3K5ZZFLJ7]$427>1R%4%B ?
MH2^_G]ZZ/=:IWOWOW7NO>_>_=>Z][TT_YHW\GWYY?)SYW]]]Y=/=6[>W!UQO
MNMV#-MK+UW9G7V!JJR/ ]5;%VMDVEQ.9W#19*C\6:P=3&HEB0NJ!Q=6!/8K[
ML/WO/8GVT]B^0^2.;^:+BWYCL4NA-&MG=RJIEOKF=*21Q,C5CD0G2QH30Y!'
M6$?NQ[+>X/-7N!S#O^R[3')MEPT11C/"A.B"*-NUG##N5AD>5>MA#X6_/OXP
M]-?&7J_K7?\ O7*XK=VV:7<T>8H*;9VZLG!3OD]Z[ES5($K\?B:BCJ->/R4+
M'0[!22IY!]D!_P"& _YGW_/E=J?^CCZJ_P#LL]SW_P 'M]V7_IM+O_N7WW_6
MCJ._^!U]UO\ HQP_]E-O_P!;.C2?\.E?##_GXN<_]%_O?_ZQ^_?\,!_S/O\
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M111(L<444:A(XXXT 5(T4     #WB]WZUUS]^]^Z]U[W[W[KW7O=I?\ *?\
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M:==5E;1X^GDJJ^KIJ&EB5GEJ:N>*F@C5$:1V>:9TC14C0L23P 3^/=@O0_\
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M(.G,48U0VYPPU$S,5; C< ]9.\C?=CV?;6AO^=;T7MR*'P(ZK #G#N:/(.&
M$%1Q8&G51'R(_F[;VW7#7;<^/^WI-@XJ=7@;>NXEI:[=TL;>/]S$XN)JG$82
M16C;3+*]8[1R?HB<!O>REMW;FWMH8'$;6VG@L/MC;.W\?2XC [=V_C:/#8/"
MXJAB6GHL;B<5CH:>AQ]!20($CABC2-%   'OFYN.Y;AO%_=[INU]-=;G<2%Y
M9I7:261V-6=W<EG9CDLQ))XGK*.UM;:QMX;.RMTAM(U"HB*%15' *J@  >0
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MZ;!I1%/DT\*7L8FE:Z*B0"G%1PX@JWS1Z77O7XX]D[*I:/[O<<&&DW'L\)'
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M_7+L]W$6V78E.Y3?$*O RBU4,.#&Z:)\D52-Z&M 85]_.:_ZL>W>YQ0O2_W
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M_P#5_OW^RW?(G_GPG=/_ **W?/\ ]8O?O]<'D+_IM]H_[++?_K9U[^KG,/\
MT8KW_G!+_P! ]>_TF=;_ //P=D?^A7@?_J_WN'_\)J]A;YV#T%\C\?OO9F[-
ME5U=W!MZLHJ'=NW<QMRKK*0;+IH6JJ6FS-'1S5%,)D*:T4KJ4B]Q[Y"_WDF]
M[+OG/'MM/LN[VMY"FTSJS02QRJK?45HQC9@#3-":TZS2^ZW87UAL/-4=]9RP
MNUY&0)$9"1X9%0& J*^G5 _\XS<. W#V'TO/@,YB,Y!3[,W)#/-A\E19.*"5
MLY2.(Y9**:9(Y&0WTD@V][)_OFWUE+U3=[][]U[KWNES^?GM7=&\_P"77O+
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M!NG:NV-\;=S&T-Y[>PN[-J[AH9L9GMN;CQE'F<'F,=4#3/19/%Y"&HHJVFE
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MWALK=\Z[JZM(0HK0ZD\9IAZT\+41D CH*[C[^^U>WJ].9/'D7\,,,SDXKAM
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@YFK_ ,7[??\ S+'_ *;_ /KGY/>E)[ZT=8G=6S>__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
